With the advent of commercial spaceflight, an increasing number of people may be heading into space in the coming years. Some will even get a chance ...
Tr1X has won an FDA green light for a clinical trial testing TRX319, a cell therapy designed to restore immune balance, for ...
Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback